BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of targeted therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317; and with Merck KGaA to research and develop on BGB-290 and BGB-283. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BGNE
CUSIPN/A
Phone34-59-494-12
Debt
Debt-to-Equity Ratio0.16
Current Ratio8.14
Quick Ratio8.10
Price-To-Earnings
Trailing P/E Ratio-52.66
Forward P/E Ratio-10.81
P/E GrowthN/A
Sales & Book Value
Annual Sales$238.39 million
Price / Sales26.48
Cash FlowN/A
Price / CashN/A
Book Value$15.02 per share
Price / Book7.82
Profitability
EPS (Most Recent Fiscal Year)($2.23)
Net Income$-93,100,000.00
Net Margins-75.19%
Return on Equity-24.14%
Return on Assets-17.84%
Miscellaneous
Employees900
Outstanding Shares53,760,000
Market Cap$6.71 billion
Beigene (NASDAQ:BGNE) Frequently Asked Questions
What is Beigene's stock symbol?
Beigene trades on the NASDAQ under the ticker symbol "BGNE."
How were Beigene's earnings last quarter?
Beigene Ltd (NASDAQ:BGNE) announced its earnings results on Thursday, August, 9th. The company reported ($2.92) EPS for the quarter, missing the consensus estimate of ($2.12) by $0.80. The company had revenue of $52.80 million for the quarter, compared to analysts' expectations of $22.53 million. Beigene had a negative net margin of 75.19% and a negative return on equity of 24.14%. The company's revenue for the quarter was up 5279999900.0% on a year-over-year basis. During the same period in the prior year, the company earned ($1.52) earnings per share. View Beigene's Earnings History.
When is Beigene's next earnings date?
What price target have analysts set for BGNE?
10 Wall Street analysts have issued 12-month price targets for Beigene's shares. Their predictions range from $138.00 to $215.00. On average, they expect Beigene's share price to reach $185.8214 in the next twelve months. This suggests a possible upside of 58.2% from the stock's current price. View Analyst Price Targets for Beigene.
What is the consensus analysts' recommendation for Beigene?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene.
What are Wall Street analysts saying about Beigene stock?
Here are some recent quotes from research analysts about Beigene stock:
- 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (10/10/2018)
- 2. Maxim Group analysts commented, "BeiGene presented preliminary data from its ongoing P1/2 study of anti- PD1 tislelizumab in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)." (9/20/2018)
Who are some of Beigene's key competitors?
Some companies that are related to Beigene include Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR) and Valeant Pharmaceuticals (VRX).
Who are Beigene's key executives?
Beigene's management team includes the folowing people:
- Mr. John V. Oyler, Founder, Chairman and Chief Exec. Officer (Age 50)
- Dr. Heng Liang Ph.D., Chief Financial Officer and Chief Strategy Officer (Age 55)
- Dr. Amy C. Peterson M.D., Chief Medical Officer of Immuno-Oncology (Age 51)
- Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 45)
- Dr. Xiaobin Wu, Pres & Gen. Mang. of China
When did Beigene IPO?
(BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.
Who are Beigene's major shareholders?
Beigene's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.15%) and Essex Investment Management Co. LLC (0.01%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for Beigene.
Which institutional investors are buying Beigene stock?
BGNE stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Essex Investment Management Co. LLC. Company insiders that have bought Beigene stock in the last two years include Bros Advisors Lp Baker and Thomas Malley. View Insider Buying and Selling for Beigene.
How do I buy shares of Beigene?
Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Beigene's stock price today?
One share of BGNE stock can currently be purchased for approximately $117.43.
How big of a company is Beigene?
Beigene has a market capitalization of $6.71 billion and generates $238.39 million in revenue each year. The company earns $-93,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Beigene employs 900 workers across the globe.
What is Beigene's official website?
How can I contact Beigene?
Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected]
MarketBeat Community Rating for Beigene (NASDAQ BGNE)
MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
